Literature DB >> 21263436

Pituitary tumors in 2010: a new therapeutic era for pituitary tumors.

Maria Gueorguiev1, Ashley B Grossman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21263436     DOI： 10.1038/nrendo.2010.233

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  8 in total

1.  Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

Authors:  Richard A Feelders; Christiaan de Bruin; Alberto M Pereira; Johannes A Romijn; Romana T Netea-Maier; Ad R Hermus; Pierre M Zelissen; Ramona van Heerebeek; Frank H de Jong; Aart-Jan van der Lely; Wouter W de Herder; Leo J Hofland; Steven W Lamberts
Journal:  N Engl J Med       Date:  2010-05-13       Impact factor: 91.245

2.  MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.

Authors:  Kalman Kovacs; Bernd W Scheithauer; Matilde Lombardero; Roger E McLendon; Luis V Syro; Humberto Uribe; Leon D Ortiz; Luis C Penagos
Journal:  Acta Neuropathol       Date:  2007-10-10       Impact factor: 17.088

3.  Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Authors:  S Petersenn; J Schopohl; A Barkan; P Mohideen; A Colao; R Abs; A Buchelt; Y-Y Ho; K Hu; A J Farrall; S Melmed; B M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

4.  Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

Authors:  Gérald Raverot; Nathalie Sturm; Florence de Fraipont; Marie Muller; Sylvie Salenave; Philippe Caron; Olivier Chabre; Philippe Chanson; Christine Cortet-Rudelli; Richard Assaker; Henry Dufour; Stephan Gaillard; Patrick François; Emmanuel Jouanneau; Jean-Guy Passagia; Michèle Bernier; Aurélie Cornélius; Dominique Figarella-Branger; Jacqueline Trouillas; Françoise Borson-Chazot; Thierry Brue
Journal:  J Clin Endocrinol Metab       Date:  2010-07-21       Impact factor: 5.958

5.  Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.

Authors:  Zachary M Bush; Janina A Longtine; Tracy Cunningham; David Schiff; John A Jane; Mary Lee Vance; Michael O Thorner; Edward R Laws; M Beatriz S Lopes
Journal:  J Clin Endocrinol Metab       Date:  2010-07-28       Impact factor: 5.958

6.  Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Authors:  M Boscaro; W H Ludlam; B Atkinson; J E Glusman; S Petersenn; M Reincke; P Snyder; A Tabarin; B M K Biller; J Findling; S Melmed; C H Darby; K Hu; Y Wang; P U Freda; A B Grossman; L A Frohman; J Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

7.  The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.

Authors:  Erika Peverelli; Luca Olgiati; Marco Locatelli; Paolo Magni; Marco Faustini Fustini; Giorgio Frank; Giovanna Mantovani; Paolo Beck-Peccoz; Anna Spada; Andrea Lania
Journal:  Cancer Lett       Date:  2009-07-19       Impact factor: 8.679

8.  Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.

Authors:  Ann I McCormack; Kerrie L McDonald; Anthony J Gill; Susan J Clark; Morton G Burt; Kirsten A Campbell; Wilton J Braund; Nicholas S Little; Raymond J Cook; Ashley B Grossman; Bruce G Robinson; Roderick J Clifton-Bligh
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-03       Impact factor: 3.478
  8 in total
  5 in total

1.  Identification of Potential Biomarkers with Diagnostic Value in Pituitary Adenomas Using Prediction Analysis for Microarrays Method.

Authors:  Hu Peng; Yue Deng; Longhao Wang; Yin Cheng; Yaping Xu; Jianchun Liao; Hao Wu
Journal:  J Mol Neurosci       Date:  2019-07-06       Impact factor: 3.444

2.  Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma.

Authors:  Youtu Wu; Jiwei Bai; Zhenye Li; Fei Wang; Lei Cao; Chunhui Liu; Shengyuan Yu; Guoqiang Yu; Yazhuo Zhang
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

3.  Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics.

Authors:  Carlotta Pozza; Chiara Graziadio; Elisa Giannetta; Andrea Lenzi; Andrea M Isidori
Journal:  J Oncol       Date:  2012-08-09       Impact factor: 4.375

4.  AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.

Authors:  I Tuominen; E Heliövaara; A Raitila; M-R Rautiainen; M Mehine; R Katainen; I Donner; V Aittomäki; H J Lehtonen; M Ahlsten; L Kivipelto; C Schalin-Jäntti; J Arola; S Hautaniemi; A Karhu
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867

5.  Components of the canonical and non-canonical Wnt pathways are not mis-expressed in pituitary tumors.

Authors:  Leandro Machado Colli; Fabiano Saggioro; Luciano Neder Serafini; Renata Costa Camargo; Helio Rubens Machado; Ayrton Custodio Moreira; Sonir R Antonini; Margaret de Castro
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.